The FDA has approved the first-ever rapid-acting insulin biosimilar, marking a major advancement in diabetes care.
Merilog is a rapid-acting human insulin analog and the first rapid-acting insulin biosimilar product approved by the FDA. Administering Merilog subcutaneously five to 10 minutes before mealtime helps improve glycemic control in patients with diabetes. Both a 3-mL single-patient-use prefilled pen and a 10-mL multiple-dose vial are included in this approval.
This innovative insulin alternative is set to enhance affordability, accessibility, and efficiency for millions of people managing diabetes worldwide.
Experts believe this approval could revolutionize treatment options, offering faster blood sugar control and improved quality of life.
What are your thoughts on this medical breakthrough? Share in the comments!